Green monkey kidney cell Vero-KO-HDAC2 and application

By optimizing sgRNA selection and CRISPR-Cas9 technology, the HDAC2 gene knockout cell line Vero-KO-HDAC2 was constructed, which solved the problem of HDAC2 knockout difficulty, significantly inhibited the replication of the ruminant virus, and provided new drug screening and Research ideas on virus replication mechanism.

CN118995569AInactive Publication Date: 2024-11-22CHINA AGRI VET BIO SCI & TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411046870.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There are difficulties in constructing HDAC2 knockout cell lines, especially when studying the replication mechanism of ruminants and developing antiviral drugs, the prior art is difficult to effectively inhibit the expression and activity of HDAC2.

Method used

By optimizing sgRNA selection and CRISPR-Cas9 technology, a monoclonal cell line Vero-KO-HDAC2 with HDAC2 gene knockout was constructed. The sgRNA targeting HDAC2 binding to CRISPR-Cas9 technology was used to achieve accurate HDAC2 gene knockout, significantly inhibiting Replication of PPRV.

Benefits of technology

The Vero-KO-HDAC2 cell line in green monkey kidney cells was successfully constructed, which can stably inhibit HDAC2 gene expression and significantly reduce the replication of the ruminant virus, providing new ideas for screening drugs that inhibit viral proliferation and studying viral replication mechanisms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995569A_ABST
    Figure CN118995569A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of gene and cell bioengineering, and particularly relates to a green monkey kidney cell Vero-KO-HDAC2 and application thereof. The invention provides a green monkey kidney cell Vero-KO-HDAC2 which is preserved in the China Center for Type Culture Collection on April 17, 2024, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: C2024114. The cell line disclosed by the invention is suitable for growing in a DMEM / F12 culture medium containing 10% of fetal calf serum, and the cells can still stably silence the HDAC2 gene and do not express HDAC2 protein after being transferred to more than 30 generations; the proliferation of the peste des petits ruminants virus in the cell line disclosed by the invention is obviously inhibited, so that the cell line can be used for research and development of medicines for preventing and treating peste des petits ruminants, and can be used for researching a replication mechanism of the peste des petits ruminants virus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of gene and cell bioengineering, and specifically relates to a green monkey kidney cell Vero-KO-HDAC2 and an application thereof. Background Art

[0002] Protein acetylation is the key to regulating gene expression and signal transduction, and is also one of the determining factors for maintaining body homeostasis. Protein acetylation is dynamically and reversibly regulated by two antagonistic enzymes: histone deacetylase (HDAC) and histone acetyltransferase (HAT). Currently, 18 HDACs have been found in mammals, which are divided into four types according to their structural characteristics. Among them, 11 types share sequence homology and are all Z n 2+ NAD-dependent HDACs include type I (HDAC1-3 and HDAC8), type II (HDAC4-7, HDAC9 and HDAC10) and type IV (HDAC11). + The dependent HDAC is type III (SIRT1~7).

[0003] HDAC2 plays an important role in cell proliferation, cell signaling, cancer occurrence and progression, inflammation and gene expression regulation. The expression and activity of HDAC2 are affected by transcription, post-transcriptional mRNA stability and post-translational regulation. Factors that affect the transcription level of HDAC2 gene include oncogenic transcription factor (β-catenin), transcription factor 4 (TCF4), proto-oncogene (MYC) and activator protein 2 (AP2). HDAC2 protein can inhibit the expression of tumor suppressor P53, promote the expression of proto-oncogene MYC, and then inhibit cell apoptosis and promote cell cycle progression; the acceleration of cell cycle progression promotes the expression of HDAC2 through feedback loops. The main factor affecting the post-transcriptional level of HDAC2 gene is mRNA stability, which is affected by RNA binding protein HUR. HUR binds to the AU-rich region of the 3'-noncoding region of HDAC2 gene mRNA to regulate the stability, translation and localization of mRNA. The post-translational level of HDAC2 protein is regulated by factors such as serine phosphorylation, lysine ubiquitination, tyrosine nitration, cysteine ​​nitrosylation and heat shock protein HSP70. Oncogenic protein kinase 2 (CK2) modifies HDAC2 phosphorylation, which can promote the enzymatic activity of HDAC2 protein and strengthen the interaction between HDAC2 and transcriptional repressors, transcription factors and promoter regions; while the cascade reaction including E1 enzyme, E2 ubiquitin conjugating enzyme UBCH8, and E3 ubiquitin ligase RLIM can catalyze HDAC2 protein polyubiquitination and proteasomal degradation. Nitration and oxidative stress can induce CK2-dependent phosphorylation of HDAC2, HDAC2 tyrosine nitration and HDAC2 proteasomal degradation; vitamin A derivative all-trans retinoic acid (ATRA) can induce HDAC2 phosphorylation through JUN kinase (JNK), acetylate and activate transcription factor KLF4 (target protein of HDAC2 protein); on the other hand, ATRA can also induce UBCH8 (also known as retinoic acid-induced gene B) to reduce HDAC2 protein levels. The activity and function of HDCA2 are also affected by endogenous metabolites such as some fatty acids and bioactive lipid mediators. For example, butyrate targets class I and class IIa HDACs and can specifically catalyze the proteasome degradation of HDAC2; sphingosine-1-phosphate selectively binds to and inhibits HDAC1 and HDAC2. In addition, NO donors specifically regulate the function of HDAC2, and S-nitrosylation of HDAC2 cysteine ​​residues separates HDAC2 from the promoter. In addition to directly modifying HDAC2, post-translational modifications also regulate the recruitment of HDAC2 protein, thereby affecting the function of HDAC2 protein.

[0004] Peste des petits ruminants (PPR) is a highly contagious disease caused by the peste des petits ruminants virus (PPRV) of the genus Morbillivirus of the family Paramyxoviridae infecting small ruminants such as goats and sheep. WOAH stipulates that PPR is a legally reportable animal disease, and my country stipulates that it is a Class I infectious disease. At present, the function of HDACs in PPRV infection is still unclear.

[0005] CRISPR-Cas9 technology is a common means of constructing gene knockout cell lines, but even on the basis of gene function inhibition, there are still many challenges in constructing gene knockout cell lines using CRISPR-Cas9. The applicant of the present invention found in the previous work that PPRV can stimulate the host HDAC2 RNA transcription level, and the inhibitor of class I HDACs MGCD0103 can significantly inhibit the replication of PPRV virus. However, there are also many difficulties in the process of constructing the knockout cell line of the HDAC2 gene. The inventors selected and optimized sgRNA, and on the basis of the random results of the method construction, screened and obtained a knockout of the HDAC2 gene, and the monoclonal cell line Vero-KO-HDAC2 that can significantly inhibit the replication of PPRV. Summary of the invention

[0006] In view of the difficulties in constructing a knockout cell line of the HDAC2 gene, the present invention obtains a knockout cell line of the HDAC2 gene by optimizing, constructing and screening sgRNA, and significantly inhibiting the replication of PPRV, which provides a new idea for screening or preparing drugs that inhibit the proliferation of PPR virus and for studying the replication mechanism of PPR virus or breeding for PPR virus resistance, specifically including the following contents:

[0007] In a first aspect, the present invention provides a green monkey kidney cell Vero-KO-HDAC2, which was deposited in the China Center for Type Culture Collection on April 17, 2024, with a deposit number of CCTCC NO: C2024114.

[0008] In a second aspect, the present invention provides the use of the green monkey kidney cell Vero-KO-HDAC2 described in the first aspect in inhibiting the proliferation of peste des petits ruminants virus.

[0009] In a third aspect, the present invention provides the use of the green monkey kidney cell Vero-KO-HDAC2 described in the first aspect in screening or preparing a drug for inhibiting the proliferation of peste des petits ruminants virus.

[0010] In a fourth aspect, the present invention provides the use of the green monkey kidney cell Vero-KO-HDAC2 described in the first aspect in preparing an in vitro screening model for anti-peste des petits ruminants virus drugs.

[0011] In a fifth aspect, the present invention provides the use of the green monkey kidney cell Vero-KO-HDAC2 described in the first aspect in preparing a cell model for studying the replication mechanism of peste des petits ruminants virus.

[0012] In a sixth aspect, the present invention provides the use of the green monkey kidney cell Vero-KO-HDAC2 described in the first aspect in preparing a cell model for breeding against peste des petits ruminants virus.

[0013] In a seventh aspect, the present invention provides an sgRNA for constructing the green monkey kidney cell Vero-KO-HDAC2 described in the first aspect, wherein the sgRNA comprises an upstream primer as shown in SEQ ID NO.1 and a downstream primer as shown in SEQ ID NO.2.

[0014] In an eighth aspect, the present invention provides a method for constructing the green monkey kidney cell Vero-KO-HDAC2 described in the first aspect, the method comprising the following steps:

[0015] (1) preparing the sgRNA described in the seventh aspect above, adding a CACC sticky end to the 5' end of the forward sequence of the sgRNA fragment, and adding an AAAC sticky end to the 5' end of the reverse sequence as sgRNA oligonucleotides;

[0016] (2) inserting the sgRNA oligonucleotide prepared in step (1) into the multiple cloning site of the lentiCRISPR v2 expression plasmid vector to obtain a recombinant vector that simultaneously expresses the Cas9 protein gene and the targeting sgRNA sequence;

[0017] (3) The recombinant vector prepared in step (2) is transfected into host cells, and puromycin-resistant positive cells are obtained by puromycin screening. A single cell line is obtained by subcloning, and green monkey kidney cells Vero-KO-HDAC2 are obtained by screening.

[0018] The beneficial effects of the present invention are as follows: first, the present invention provides an sgRNA that specifically targets the HDAC2 gene, and the sgRNA can specifically target the HDAC2 gene, and combined with the CRISPR-Cas9 technology, the HDAC2 gene can be knocked out in the host cell, with accurate targeting and high knockout efficiency; secondly, the present invention uses the sgRNA to construct and screen a HDAC2 gene knockout monoclonal cell line Vero-KO-HDAC2 through the CRISPR-Cas9 technology, and can significantly inhibit the replication of PPRV. The monoclonal cell line was sent to the China Type Culture Collection for preservation on April 17, 2024, and was classified and named as green monkey kidney cell Vero-KO-HDAC2, with a preservation number of CCTCC NO: C2024114, deposit address: Wuhan University, Wuhan, China; the green monkey kidney cell Vero-KO-HDAC2 cell morphology is similar to that of Vero cells, being nearly round, with strong cell refractive index, full cytoplasm and clear nucleoplasm; it is suitable for growing in a DMEM / F12 culture medium containing 10% fetal bovine serum, and the cell can stably silence the HDAC2 gene after being passed for more than 30 generations, and does not express the HDAC2 protein, with good stability; the green monkey kidney cell Vero-KO-HDAC2 can significantly inhibit the replication of PPRV, providing a new idea for screening or preparing drugs for inhibiting the proliferation of peste des petits ruminants virus, and for studying the replication mechanism of peste des petits ruminants virus or breeding for resistance to peste des petits ruminants virus. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 lentiCRISPR-HDAC2-sgRNA knockout plasmid construction sequencing peak diagram;

[0020] Figure 2 Western Blot identification of Vero-KO-HDAC2 cell line;

[0021] Figure 3 PPRV replication assay in Vero-KO-HDAC2 cells;

[0022] Figure 4 Partial sequence alignment of Vero-KO-HDAC2 cell line near the knockout sequence;

[0023] Figure 5 Growth curve of Vero-KO-HDAC2 cells;

[0024] Figure 6 Western Blot analysis of serially passaged Vero-KO-HDAC2 cells. DETAILED DESCRIPTION

[0025] In order to make the purpose, technical scheme and advantages of the present invention clearer, the embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings. However, it will be appreciated by those skilled in the art that in the embodiments of the present invention, many technical details are provided to enable the reader to better understand the present application. However, even without these technical details and various changes and modifications based on the following embodiments, the technical scheme claimed in the present application can be implemented.

[0026] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds.

[0027] definition

[0028] The term "sgRNA" stands for guide RNA, which refers to a small non-coding RNA that guides the insertion or deletion of uridine residues into the kinetoplastid during the RNA editing process.

[0029] The present invention artificially synthesizes sgRNA targeting the HDAC2 gene, further adds a CACC sticky end to the 5' end of the forward sequence of the sgRNA fragment, and adds an AAAC sticky end to the 5' end of the reverse sequence to prepare an sgRNA oligonucleotide targeting the HDAC2 gene, and anneals it into a double-stranded fragment;

[0030] Based on direct targeted splicing of the HDAC2 gene, the present invention utilizes a CRISPR / Cas9 combined specific knockout method for the HDAC2 gene to knock out the HDAC2 gene in Vero cells, thereby obtaining a Vero-KO-HDAC2 cell for constructing a cell line with resistance to PPRV replication and a PPRV-resistant breeding project.

[0031] The experimental methods in the following examples are conventional methods unless otherwise specified; the experimental materials used in the following examples are purchased from conventional biochemical reagent companies unless otherwise specified.

[0032] The sources of the plasmids involved in the following examples were purchased from Miaoling Plasmid Platform.

[0033] PPRV (Nigeria / 75 / 1 strain, gene accession number HQ197753) was obtained from the Herbivore Virus Disease Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences.

[0034] Example 1 Design of sgRNA targeting HDAC2 gene

[0035] The NCBI database was used to query and find the complete genome sequence of the green monkey HDAC2 gene (GenBank accession number: NW_023666040.1), and the first two exon segments of HDAC2 in the genomic transcript were located for target design.

[0036] According to the CRISPR / Cas9 design principle, the CRISPR online design website http: / / crispor.tefor.net / was logged in to design sgRNA, and two pairs of 20bp sgRNA fragments were selected according to the score, and they were named as: HDAC2-sgRNA1 (HDAC2-sgRNA1-F, shown in SEQ ID NO.1; HDAC2-sgRNA1-R, shown in SEQ ID NO.2), HDAC2-s gRNA2 (HDAC2-sgRNA2-F, SEQ ID NO.3; HDAC2-sgRNA2-R, SEQ ID NO.4); CACC sticky end was added to the 5' end of the forward sequence of the sgRNA fragment, and AAAC sticky end was added to the 5' end of the reverse sequence, as sgRNA oligonucleotides (sgRNA1-oligo) targeting the HDAC2 gene. The sgRNA1-oligo was synthesized by Shanghai Shenggong Biotechnology Co., Ltd., and the detailed sequence is shown in Table 1.

[0037] Table 1 sgRNA oligonucleotides targeting HDAC2 gene

[0038]

[0039] Note: The underlined sequence is the sticky end, and the ununderlined sequence is the sgRNA sequence.

[0040] Example 2 Construction of sgRNA recombinant plasmid lentiCRISPR-HDAC2-sgRNA

[0041] The lentiCRISPR v2 vector was digested with restriction endonuclease BsmBI, 60 μL of digestion system: lentiCRISPRv2 vector, 10 μL; BsmBI, 3 μL; 10×FastDigest Buffer, 6 μL; FastAP, 3 μL; 100 mM DTT, 0.6 μL; ddH2O, 37.4 μL, mixed and incubated in a 37°C water bath for 1 hour. Then, the linearized fragment of the lentiCRISPR v2 vector containing sticky ends was purified and recovered using nucleic acid electrophoresis and Omega's DNA purification and recovery kit.

[0042] The two pairs of sgRNA-oligo synthesized in Example 1 were diluted to 100 μM respectively, and a total of 10 μL reaction system was prepared: 1 μL upstream primer; 1 μL downstream primer; 10×T4 Ligation Buffer, 1 μL; 6.5 μL ddH2O; 0.5 μL T4 PNK; reaction procedure: 37°C, 30 min; 95°C, 5 min; 5°C / min cooling to 25°C. After the reaction, the double-stranded sgRNA-oligo was diluted with ddH2O at 1:200 and stored at 4°C.

[0043] The purified and recovered lentiCRISPR v2 linearized fragment product was ligated with the double-stranded sgRNA-oligo. Reaction system: 2×Quick Ligase Buffer, 0.55μL; lentiCRISPR v2 enzyme-cleaved purified fragment, 100ng; diluted double-stranded sgRNA-oligo, 1μL; supplemented to 10μL with deionized water, and then added 1μL QuickLigase. Connect at 25℃ for 10min, and transform the ligation product into Stbl3 Escherichia coli competent cells. The transformation procedure is: mix 50μL Stbl3 competent cells with the ligation product, place on ice for 30min, heat shock in a 42℃ water bath for 45sec, take out the ice bath for 5min, add 1mL of non-resistant LB culture medium, and culture at 37℃ and 220rpm for 1h; then aspirate 200μL of bacterial solution to spread the transformed Escherichia coli on an LB plate with ampicillin resistance, and culture at 37℃ incubator for 12-16h. Pick a single clone and culture it in LB liquid medium containing ampicillin antibiotic resistance at 37℃220rpm for 12-16h. The plasmid was extracted using a plasmid extraction kit and verified by sequencing.

[0044] The sequencing results of the recombinant plasmid are as follows Figure 1 As shown, the sequencing results were consistent with the expected results, indicating that the plasmids lentiCRISPR-HDAC2-sgRNA1 and lentiCRISPR-HDAC2-sgRNA2 expressing sgRNA were successfully constructed.

[0045] Example 3 Lentivirus packaging

[0046] Vero cells were revived before transfection and cultured in T25 cell flasks with DMEM medium containing 10% FBS. When the cells were passaged 2 to 3 times and the properties were stable and in good condition, the cells were digested and spread in 10 cm cell culture dishes. 4 μg of each of the recombinant plasmids (lentiCRISPR-HDAC2-sgRNA1 and lentiCRISPR-HDAC2-sgRNA2) successfully constructed in Example 2, 4 μg of psPAX2 plasmid, and 2 μg of pMD2.G plasmid were mixed in 500 μL jetPRIME buffer, vortexed for 10 seconds, and centrifuged instantaneously; then 20 μL jetPRIME was added to the plasmid mixture, vortexed for 1 second, and centrifuged instantaneously. After incubating the transfection reagent and plasmid mixture at room temperature for 20 minutes, cells with a fusion degree of 70% to 80% were directly added. The cells were placed back in a 37°C, 5% CO2 incubator and cultured for 48 h. The supernatant was collected and centrifuged at 4°C, 3000 rpm / min. The supernatant was filtered through a PES filter (0.22 μm) and then divided for use. The two lentiviruses were labeled as LV-HDAC2-sgRNA1 and LV-HDAC2-sgRNA2, respectively.

[0047] Example 4 Screening and identification of HDAC2 gene knockout Vero cell lines

[0048] 1. Infect cells with lentivirus

[0049] Vero cells were revived before infection with lentivirus, and cultured in T25 cell flasks with DMEM medium containing 10% FBS. When the cells were passaged 2 to 3 times and the properties were stable and in good condition, the cells were digested and plated in a six-well cell plate. When the cell confluence reached 40% to 60%, the lentivirus LV-HDAC2-sgRNA1 and LV-HDAC2-sgRNA2 successfully packaged in Example 3 were used to infect Vero cells, 2 ml LV-HDAC2-sgRNA1 or LV-HDAC2-sgRNA2 and 10 μg / ml polybrene were added to each well, and the cells were placed in a 37°C, 5% CO2 incubator for culture. After 24 hours, new culture medium was used to continue culture for 48 hours. After 72 hours of lentivirus infection, puromycin antibiotics were used for selection for 96 hours.

[0050] 2. Western Blot Identification of HDAC2 Gene Knockout Vero Cell Line

[0051] The cells selected by puromycin were subjected to limiting dilution and monoclonal cells were selected. The cells were digested with 0.25% trypsin, and an appropriate amount of culture medium was added to blow evenly, and 100 μL of cell suspension was aspirated for cell counting. According to the counting results, the serum-free medium was used for limiting dilution method, and the cells were diluted to 200 cells / mL in 10-fold ratios. The diluted cell suspension was added to the first two columns of the 96-well plate, 100 μL was added to each well, and then diluted to the 96-well plate in 2-fold ratios with a 100 μL pipette, and two rows of culture wells were laid for each concentration gradient. After 4 to 6 days of culture, the double cell wells and multi-cell wells were removed, and the single cell wells with normal cell morphology were marked, and the culture was continued for about 8 to 10 days; after confirming that the monoclonal cell clusters were growing well, the monoclonal cell clusters selected in the 96-well plate were digested with trypsin, and transferred to the 48-well plate for continued subculture. After the cells were fully grown, they were transferred to the 24-well plate, 12-well plate, and 6-well plate for amplification culture.

[0052] Six knockout candidate cell lines (including three cell lines corresponding to sgRNA1, Vero-KO-HDAC2-1, Vero-KO-HDAC2-2, Vero-KO-HDAC2-3 and three cell lines corresponding to sgRNA2, Vero-KO-HDAC2-4, Vero-KO-HDAC2-5, Vero-KO-HDAC2-6) were selected and cultured separately. After the cells were fully grown, a part of the cells was taken to extract the total cell protein, and the protein concentration was measured by the BCA method. The concentration of each protein sample was adjusted to a consistent level with protein lysis buffer, and 5× protein loading buffer was added and boiled in a water bath for 5 minutes. After instantaneous centrifugation, SDS-PAGE electrophoresis and Western Blot identification were performed.

[0053] The identification results are as follows Figure 2 As shown, HDAC2 protein bands were still detected in Vero-KO-HDAC2-1 and Vero-KO-HDAC2-6, indicating that the above two cell lines failed to achieve HDAC2 knockout; while the internal reference protein β-Actin in Vero-KO-HDAC2-2, Vero-KO-HDAC2-3, Vero-KO-HDAC2-4 and Vero-KO-HDAC2-5 samples was normal, and there was no HDAC2 protein band, which were the four HDAC2 gene knockout cell lines preliminarily identified.

[0054] Example 5 Screening of HDAC2 gene knockout cell lines that inhibit PPRV replication

[0055] Vero-KO-HDAC2-2, Vero-KO-HDAC2-3, Vero-KO-HDAC2-4, Vero-KO-HDAC2-5 and wild-type Vero cells were subcultured normally, and equal amounts of cells were plated into 12-well cell culture dishes, inoculated with Nigeria / 75 / 1 strain PPRV at an MOI of 0.01, and cell samples were collected 120 h after infection. Western Blot, RT-qPCR and TCID 50 Methods To detect the replication of PPRV.

[0056] The results are as follows Figure 3 As shown, compared with wild-type Vero cells, the PPRV N RNA level in the Vero cell HDAC2 gene knockout cell line Vero-KO-HDAC2-2, in which HDAC2-sgRNA1 targets the HDAC2 gene, is significantly higher than that in wild-type Vero cells. Figure 3 As shown in B, P<0.002) and protein expression ( Figure 3 As shown in A, P<0.002) were significantly reduced, and the virus titer was reduced by about 3 times ( Figure 3 (C, P<0.033). However, there was no significant difference in the replication of PPRV in Vero-KO-HDAC2-3, Vero-KO-HDAC2-4, Vero-KO-HD AC2-5 and Vero-WT. This indicates that only the knockout of HDAC2 in Vero-KO-HDAC2-2 inhibits the replication of PPRV, which can be used to study the replication mechanism of PPRV virus and provide new ideas for the development of anti-PPRV drugs.

[0057] Example 6 Gene sequence and stability analysis of HDAC2 gene knockout Vero cell line

[0058] According to the randomness of the integration site, the integration of exogenous genes into the chromosomes of host cells may cause problems such as poor host cell status, weak response to signal molecules, and poor expression stability of the target gene. Therefore, the cell strain Vero-KO-HDAC2-2 and wild-type Vero cells obtained from Example 5 were continuously expanded and cultured, and when the number of cells reached a certain scale, the HDAC2 gene sequencing, cell growth curve comparison test and HDAC2 gene expression stability analysis of the Vero cell line were performed.

[0059] 1. Sequencing and Identification of HDAC2 Gene in Vero-KO-HDAC2-2 Cell Line

[0060] Vero-KO-HDAC2-2 cells were digested with 0.25% trypsin, centrifuged at 5000rpm for 5min, the supernatant was removed, total cell DNA was extracted, and HDAC2 gene DNA check primers were used for amplification. Amplification 50μL reaction system: PrimeSTAR GXLPremix Fast, Dye plus (2×) 25μL; DNA template 100ng; knockout cell line identification primers 10pmol each, ddH2O supplemented to 50μL; amplification primers Vero-HDAC2-Check1-F (5'-CCACGTTTCCCTTAGCCCTT-3', shown in SEQ ID NO.5) and Vero-HDAC2-Check1-R (5'-CTTGTCTCCTGCCTTTCCCC-3', shown in SEQ ID NO.6). Amplification program: 98℃, 3min; 98℃, 10sec, 60℃, 5sec, 68℃, 30sec, 35 cycles; 68℃, 10min; 4℃ storage. Take 10 μL of PCR product for agarose gel electrophoresis identification.

[0061] Recover the PCR product of the expected size fragment and connect it with the PMD-19T vector. 10μL system: pMD19-TVector 0.5μL, SolutionI 5μL, PCR recovery product 4.5μL; react at 16℃ for 2h. Add the ligation product to 50μL Trans5α competent cells and place on ice for 30min; heat at 42℃ for 45sec, and then place on ice for 5min; add 500μL resistance-free LB medium and shake culture at 37℃ for 60min. Take 200μL of bacterial solution and evenly spread it on the agar plate medium containing Amp for culture, and culture at 37℃ for 12h; select 3 white colonies for each sample and sequence them using pM19-T Vector universal primers.

[0062] The cell line Vero-KO-HDAC2-2 was identified as a monoclonal cell line with HDAC2 gene knockout by sequencing. Compared with the wild-type sequence, the HDAC2 gene knockout cell line had a 1 nucleotide deletion and was named Vero-KO-HDAC2 (eg Figure 4 shown).

[0063] 2. Stability Analysis of Vero-KO-HDAC2 Cell Line

[0064] When the confluence of Vero-KO-HDAC2 cells reached 80%, cells were digested and counted. 4Cells were plated on a 6-well cell culture plate at a cell density of 10 cells / well. Three replicate wells were set up in each group. Complete DMEM medium was used for culture, with 2 mL per well. The cells were digested with trypsin at 12, 24, and 48 hours, and cell samples were collected for cell proliferation analysis using a counterstar cell counter. The results are shown in Figure 5 As shown, the growth rate of the Vero-KO-HDAC2 cell line is slightly lower than that of the wild-type Vero cell line, but the growth curve trends are consistent.

[0065] At the same time, the total protein of Vero-KO-HDAC2 cells cultured to 10, 15, 20, 25 and 30 generations was collected and compared with the total protein extract of Vero-WT cells for Western Blot detection. The results showed that the HDAC2 protein of the Vero-KO-HDAC2 cell line could not be detected after 30 generations of continuous subculture, while the HDAC2 protein of the Vero-WT cells in the control group was normally expressed ( Figure 6 As shown). This proves that the Vero-KO-HDAC2 cell line has good growth activity and stability and is a good knockout cell line.

[0066] In summary, the present invention successfully constructed a cell line with loss of function of the protein encoded by the HDAC2 gene (HDAC2 gene knockout Vero cell line, Vero-KO-HDAC2-2) through CRISPR-Cas9 technology, named green monkey kidney cell Vero-KO-HDAC2, and sent it to the China Type Culture Collection for preservation on April 17, 2024, with the preservation number: CCTCC NO: C2024114, the preservation address: Wuhan University, Wuhan, China, and the contact number is (027) 68752319.

[0067] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A green monkey kidney cell Vero-KO-HDAC2, characterized in that The green monkey kidney cell Vero-KO-HDAC2 was deposited in the China Center for Type Culture Collection on April 17, 2024, with the deposit number being CCTCC NO: C2024114.

2. Use of the green monkey kidney cell Vero-KO-HDAC2 as claimed in claim 1 in inhibiting the proliferation of peste des petits ruminants virus.

3. Use of the green monkey kidney cell Vero-KO-HDAC2 according to claim 1 in screening or preparing a drug for inhibiting the proliferation of peste des petits ruminants virus.

4. Use of the green monkey kidney cell Vero-KO-HDAC2 as claimed in claim 1 in preparing an in vitro screening model for anti-peste des petits ruminants virus drugs.

5. Use of the green monkey kidney cell Vero-KO-HDAC2 as claimed in claim 1 in preparing a cell model for studying the replication mechanism of peste des petits ruminants virus.

6. Use of the green monkey kidney cell Vero-KO-HDAC2 according to claim 1 in preparing a cell model for breeding against peste des petits ruminants virus.

7. A sgRNA for constructing the green monkey kidney cell Vero-KO-HDAC2 according to claim 1, characterized in that: The sgRNA has an upstream primer as shown in SEQ ID NO.1 and a downstream primer as shown in SEQ ID NO.

2.

8. The method for constructing the green monkey kidney cell Vero-KO-HDAC2 according to claim 1, characterized in that: The method comprises the following steps: (1) preparing the sgRNA according to claim 7, adding a CACC sticky end to the 5' end of the forward sequence of the sgRNA fragment, and adding an AAAC sticky end to the 5' end of the reverse sequence as an sgRNA oligonucleotide; (2) inserting the sgRNA oligonucleotide prepared in step (1) into the multiple cloning site of the lentiCRISPR v2 expression plasmid vector to obtain a recombinant vector that simultaneously expresses the Cas9 protein gene and the targeting sgRNA sequence; (3) The recombinant vector prepared in step (2) is transfected into host cells, and puromycin-resistant positive cells are obtained by puromycin screening. A single cell line is obtained by subcloning, and green monkey kidney cells Vero-KO-HDAC2 are obtained by screening.

Citation Information

Patent Citations

  • HDAC2 gene knockout BHK-21 cell line as well as construction method and application thereof

    CN112877275A

  • Cell line with HDAC1 gene knocked out, construction method and application

    CN118185876A